Ann: NOX to Present Clinical Data at COSA Annual Meeting, page-9

Implied from what?

"In patients whose tumours are difficult to measure, clinical response is being determined on the basis of PSA levels and pain scores.

Cohort 1 (400 mg Veyonda: 3 patients (Patients # 1-3) were assessed at 12 weeks as having stable disease by scan (RECIST assessment). At 24 weeks, Patients #1 and 3 remain stable on the basis of scans, while Patient # 2 has progressed.

Cohort 2 (800 mg): 1 patient (#7) was assessed at 12 weeks as having a partial response. At 24 weeks this patient continues to have a partial response including a strong decreasing PSA response. Cohort 3 (1,200 mg): Patient #9 at 12 weeks continues to have a partial response and a strong decreasing PSA response.